GPD2 and the Glucose Link to Motion Sickness
One in three people experiences clinically significant motion sickness, yet the
biological reasons have long been obscure. In 2015, Hromatka et al.11 Hromatka et al.
Genetic
variants associated with motion sickness point to roles for inner ear development,
neurological processes and glucose homeostasis. Human Molecular Genetics
published the first genome-wide association study of motion sickness in 80,494
individuals from 23andMe — and found 35 genome-wide-significant loci spanning
inner-ear development, neurological processes, and, unexpectedly, glucose
homeostasis. The second strongest signal in the entire study was rs56051278,
located in an intron of GPD2 on chromosome 2 (P = 1.5×10⁻²⁹, beta = +0.066
per G allele).
The Mechanism
GPD2 encodes mitochondrial glycerol-3-phosphate dehydrogenase22 mitochondrial glycerol-3-phosphate dehydrogenase
a FAD-dependent
enzyme on the inner mitochondrial membrane that oxidises glycerol-3-phosphate to
dihydroxyacetone phosphate, transferring electrons into the mitochondrial electron
transport chain and regenerating cytosolic NAD⁺ from NADH produced during glycolysis —
a process called the glycerol phosphate shuttle.
This shuttle is critical for sustaining glycolysis in tissues that rely on rapid
glucose oxidation, including neurons and intestinal smooth muscle cells.
rs56051278 is an intronic variant, but it is in high linkage disequilibrium
(r² ≈ 0.8)33 high linkage disequilibrium
(r² ≈ 0.8)
LD means these two variants are nearly always inherited together
with rs2116665, a missense variant in GPD2 (R264H) previously associated with
elevated free fatty acid and glycerol levels in plasma — biomarkers of glucose intolerance.
The downstream physiology connects to the GI tract in a specific way: during
vestibular stimulation, glucose regulation is perturbed. A dedicated experimental
study by Mo et al. 201244 Mo et al. 2012
Acute hyperglycemia is related to gastrointestinal
symptoms in motion sickness. Physiological Behavior
found that individuals who developed nausea and vomiting during motion exposure
had significantly lower pre-exposure insulin than those who did not (P<0.05),
and that acute hyperglycemia was
greater in the symptomatic group. In a rat arm of the same study, pre-treating
animals with insulin before acceleration significantly reduced the motion sickness
index. The authors concluded that "stable glucose levels can help to relieve
gastrointestinal symptoms in motion sickness." GPD2's role in sustaining neuronal
and smooth-muscle glucose metabolism positions it as a plausible biological link
between this genetic signal and the clinical phenotype.
The Evidence
The Hromatka GWAS enrolled 80,494 individuals of European ancestry drawn from the 23andMe cohort. Motion sickness susceptibility was self-reported. rs56051278 reached P = 1.5×10⁻²⁹ with a beta of +0.066 per G allele (effect allele). This is a well-powered association — the signal at the GPD2 locus was among the top two genome-wide.
The glucose-homeostasis cluster of hits (also including variants near UBE2E2, GPR26, RGS5, and NR2F2) was highlighted as a biologically coherent group distinct from the inner-ear development loci.
Interactions
rs56051278 is a tag SNP for the missense variant rs2116665 (R264H in GPD2) — the two are in high LD (r² ≈ 0.8) and should not be treated as independent associations. Future analysis comparing carriers of both to carriers of only one tag should be interpreted cautiously. The strongest hit in the same GWAS was rs66800491 near PVRL3.